Novartis (NOVN) Status Update summary

Financial Outlook and Growth Guidance

• Upgraded mid-term sales guidance to 6% CAGR for 2023-2028 and 5% CAGR for 2024-2029, reflecting strong momentum, robust pipeline, and upcoming product launches with US exclusivity into the 2030s.

• Margin profile expected to reach 40%+ by 2027, with incremental improvements each year, though more muted in 2025-2026 due to LOE headwinds.

• After 2026, limited LOE exposure until Cosentyx expiry at the end of the decade, supporting a solid growth run.

• Share buybacks and growing dividends remain a consistent part of capital allocation, supported by strong cash flow and a $15bn buyback program with $7bn remaining.

• Mid-single digit growth aspiration continues beyond 2029, with modeling that includes pipeline assets and long product tails in emerging markets.

Margin and Capital Allocation

• Margin improvements are expected annually, with a focus on reaching and maintaining 40%+ core margin, prioritizing investment in launches and R&D over pushing margins higher.

• Gross margin currently exceeds 80%, but product mix (e.g., Leqvio, Pluvicto) may influence future margin trends.

• CapEx is expected to remain stable at 2-3% of sales, with targeted investments in RLT capacity and no major increases anticipated.

• The company maintains flexibility to balance M&A, dividend growth, and share buybacks without trade-offs.

• Value-creating bolt-on acquisitions and strategic deals remain a key part of capital allocation policy.

Strategic Transformation and Commercial Execution

• Transitioned to a pure-play innovative medicines company, divesting non-core assets and spinning off Sandoz, resulting in a 36% increase in market capitalization since 2018 and $50bn in dividends paid from 2018-2024.

• Commercial execution has improved due to structural simplification, unified leadership, and focused investment in key brands and geographies.

• Enhanced market access and field force execution, especially in the U.S., Germany, China, and Japan, drive growth.

• AI-driven resource allocation optimizes established brands, supporting stable performance even with reduced investment.

• Hosted investor events and provided transparent updates to stakeholders.